Researcher:
Yalçın, Can Ege

Profile Picture
ORCID

Job Title

Undergraduate Student

First Name

Can Ege

Last Name

Yalçın

Name

Name Variants

Yalçın, Can Ege

Email Address

Birth Date

Filters

2016 - 20185

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.13792881-e824-410a-b8fd-589ccd9c4330

Search Results

Now showing 1 - 5 of 5
  • Placeholder
    PublicationMetadata only
    Brain-kidney cross-talk: definition and emerging evidence
    (Elsevier, 2016) Afsar, Baris; Siriopol, Dimitrie; Goldsmith, David; Covic, Adrian; N/A; Kanbay, Mehmet; Sağ, Alan Alper; Yalçın, Can Ege; Kaya, Eren; Faculty Member; Faculty Member; Undergraduate Student; Undergraduate Student; School of Medicine; School of Medicine; School of Medicine; School of Medicine; 110580; N/A; N/A; N/A
    Cross-talk is broadly defined as endogenous homeostatic signaling between vital organs such as the heart, kidneys and brain. Kidney-brain cross-talk remains an area with excitingly few publications despite its purported clinical relevance in the management of currently undertreated conditions such as resistant hypertension. Therefore, this review aims to establish an organ-specific definition for kidney-brain cross-talk and review the available and forthcoming literature on this topic.
  • Placeholder
    PublicationMetadata only
    Who can get the next nobel prize in infectious diseases?
    (Elsevier Sci Ltd, 2016) N/A; N/A; N/A; N/A; N/A; N/A; N/A; Ergönül, Önder; Yalçın, Can Ege; Erkent, Mahmut Alp; Demirci, Mert; Uysal, Sanem Pınar; Ay, Nur Zeynep; Ömeroğlu, Asena; Faculty Member; Undergraduate Student; Undergraduate Student; Undergraduate Student; Undergraduate Student; Undergraduate Student; Undergraduate Student; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; Koç University Hospital; 110398; N/A; N/A; N/A; N/A; N/A; N/A
    The aim of this paper is to deliver a perspective on future Nobel prizes by reviewing the features of Nobel prizes awarded in the infectious diseases-related (IDR) field over the last 115 years. Thirty-three out of 106 Nobel prizes (31%) in Physiology or Medicine have been awarded for IDR topics. Out of 58 Nobel laureates for IDR topics, two have been female; 67% have been medical doctors. The median age of Nobel laureates in Physiology or Medicine was found to be lower than the median age of laureates in Literature (p < 0.001). Since the Second World War, US-affiliated scientists have dominated the Nobel prizes (53%); however before 1945, German scientists did so (p = 0.005). The new antimicrobials received Nobel prizes until 1960; however no treatment study was awarded the Prize until the discovery of artemisinin and ivermectin, for which the Nobel Prize was awarded in 2015. Collaborative works have increasingly been appreciated. In the future, more female laureates would be expected in the IDR field. Medical graduates and scientists involved in multi-institutional and multidisciplinary collaborative efforts seem to have an advantage. (C) 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
  • Placeholder
    PublicationMetadata only
    Hypertension as an autoimmune and inflammatory disease
    (Nature Publishing Group (NPG), 2016) Solak, Yalcin; Afsar, Baris; Vaziri, Nosratola D.; Covic, Adrian; N/A; Aslan, Gamze; Yalçın, Can Ege; Kanbay, Mehmet; Doctor; Undergraduate Student; Faculty Member; N/A; School of Medicine; School of Medicine; Koç University Hospital; N/A; N/A; 110580
    Hypertension that is considered idiopathic is called essential hypertension and accordingly has no clear culprit for its cause. However, basic research and clinical studies in recent years have expanded our understanding of the mechanisms underlying the development of essential hypertension. of these, increased oxidative stress, both in the kidney and arterial wall, closely coupled with inflammatory infiltration now appear to have a prominent role. Discovery of regulatory and interleukin-17-producing T cells has enabled us to better understand the mechanism by which inflammation and autoimmunity, or autoinflammation, lead to the development of hypertension. Despite achieving considerable progress, the intricate interactions between oxidative stress, the immune system and the development of hypertension remain to be fully elucidated. In this review, we summarize recent developments in the pathophysiology of hypertension with a focus on the oxidant stress-autoimmunity-inflammation interaction.
  • Placeholder
    PublicationMetadata only
    Reply to: The triglyceride to high-density lipoprotein cholesterol ratio is a useful marker to predict unfavorable cardiovascular outcomes, but other confounding factors should be considered
    (Wiley, 2016) Turak, Osman; Yalçın, Can Ege; Kanbay, Mehmet; Undergraduate Student; Faculty Member; School of Medicine; School of Medicine; N/A; 110580
    N/A
  • Thumbnail Image
    PublicationOpen Access
    Capecitabine-induced bilateral ectropion: a rare ocular manifestation requiring surgical intervention
    (Medknow Publications, 2018) N/A; N/A; Tatar, Sedat; Yalçın, Can Ege; Sezgin, Billur; Taş, Ayşe Yıldız; Müftüoğlu, Orkun; Özmen, Selahattin; Faculty Member; Faculty Member; Faculty Member; Faculty Member; School of Medicine
    It has been established that many chemotherapeutic agents are associated with a variety of ocular side effects. As an antineoplastic agent, 5-fluorouracil (5-FU) is the chemotherapeutic agent that is frequently linked with cicatricial ectropion. Capecitabine is a prodrug of 5-FU and has a more favorable side effect profile than 5-FU. Frequent side effects of capecitabine include gastrointestinal events and hand-foot-mouth syndrome; cicatricial ectropion is rather uncommon. Enzyme deficiencies affecting the capecitabine metabolism have been reported to be associated with exaggerated generalized systemic and cutaneous side effects; however, there are no cases in the literature reporting capecitabine-induced isolated bilateral-progressive ectropion. Although cessation of the agent is frequently sufficient for the treatment of ectropion, close follow-up is indicated in such patients as permanent damage may occur if the problem is left untreated. We report a case of capecitabine-induced bilateral cicatricial ectropion refractory to treatment cessation, ultimately requiring surgical treatment.